Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.

Bonnet E, Mastier C, Lardy-Cléaud A, Rochefort P, Sarabi M, Guibert P, Cattey-Javouhey A, Desseigne F, de La Fouchardière C.

Curr Oncol. 2019 Aug;26(4):e466-e472. doi: 10.3747/co.26.4903. Epub 2019 Aug 1.

2.

Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas.

Surun A, Varlet P, Brugières L, Lacour B, Faure-Conter C, Leblond P, Bertozzi-Salomon AI, Berger C, André N, Sariban E, Raimbault S, Prieur F, Desseigne F, Zattara H, Guimbaud R, Polivka M, Delisle MB, Vasiljevic A, Maurage CA, Figarella-Branger D, Coulet F, Guerrini-Rousseau L, Alapetite C, Dufour C, Colas C, Doz F, Bourdeaut F.

Neuro Oncol. 2020 Jan 11;22(1):128-138. doi: 10.1093/neuonc/noz154.

PMID:
31504825
3.

Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.

Rochefort P, Lardy-Cleaud A, Sarabi M, Desseigne F, Cattey-Javouhey A, de la Fouchardière C.

Oncologist. 2019 Dec;24(12):1543-1548. doi: 10.1634/theoncologist.2018-0786. Epub 2019 Jun 4.

4.

Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

de la Fouchardière C, Cohen R, Malka D, Guimbaud R, Bourien H, Lièvre A, Cacheux W, Artru P, François E, Gilabert M, Samalin-Scalzi E, Zaanan A, Hautefeuille V, Rousseau B, Senellart H, Coriat R, Flippot R, Desseigne F, Lardy-Cleaud A, Tougeron D.

Oncologist. 2019 Dec;24(12):e1331-e1340. doi: 10.1634/theoncologist.2018-0914. Epub 2019 May 31.

5.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparicio T, Hoeffel C; PRODIGE 9 Investigators and PRODIGE 20 Investigators.

Gut. 2019 May 17. pii: gutjnl-2018-316407. doi: 10.1136/gutjnl-2018-316407. [Epub ahead of print]

PMID:
31101691
6.

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

Trédan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardière A, Fayette J, Desseigne F, Ray-Coquard I, de la Fouchardière C, Frappaz D, Heudel PE, Bonneville-Levard A, Fléchon A, Sarabi M, Guibert P, Bachelot T, Pérol M, You B, Bonnin N, Collard O, Leyronnas C, Attignon V, Baudet C, Sohier E, Villemin JP, Viari A, Boyault S, Lantuejoul S, Paindavoine S, Treillleux I, Rodriguez C, Agrapart V, Corset V, Garin G, Chabaud S, Pérol D, Blay JY; ProfiLER investigators.

Ann Oncol. 2019 May 1;30(5):757-765. doi: 10.1093/annonc/mdz080.

PMID:
30865223
7.

Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report.

Rochefort P, Roussel J, de la Fouchardière A, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Mastier C, Neidhardt-Berard EM, de la Fouchardière C.

Immunotherapy. 2018 Aug;10(10):831-835. doi: 10.2217/imt-2018-0011.

PMID:
30073896
8.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12. Erratum in: JAMA Oncol. 2019 May 1;5(5):745.

9.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Jacquot S, Genet D, Khemissa F, Suc E, Desseigne F, Texereau P, Lepage C, Bennouna J; PRODIGE 9 Investigators.

J Clin Oncol. 2018 Mar 1;36(7):674-681. doi: 10.1200/JCO.2017.75.2931. Epub 2018 Jan 18.

PMID:
29346040
10.

Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).

Robert M, Jarlier M, Gourgou S, Desseigne F, Ychou M, Bouché O, Juzyna B, Conroy T, Bennouna J.

Oncology. 2017;93(6):367-376. doi: 10.1159/000477850. Epub 2017 Oct 6.

PMID:
28982109
11.

Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.

Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C.

Oncol Lett. 2017 Jun;13(6):4917-4924. doi: 10.3892/ol.2017.6061. Epub 2017 Apr 20.

12.

Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.

Fattouh K, Collet-Benzaquen D, Provensal AM, Desseigne F, Castillo C, Combemale P, de la Fouchardière A.

Am J Dermatopathol. 2017 Oct;39(10):764-766. doi: 10.1097/DAD.0000000000000743.

PMID:
27779486
13.

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.

Péron J, Roy P, Conroy T, Desseigne F, Ychou M, Gourgou-Bourgade S, Stanbury T, Roche L, Ozenne B, Buyse M.

Oncotarget. 2016 Dec 13;7(50):82953-82960. doi: 10.18632/oncotarget.12761.

14.

Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues.

Brieau B, Lepère C, Walter T, Lecomte T, Guimbaud R, Manfredi S, Tougeron D, Desseigne F, Lourenco N, Afchain P, El Hajbi F, Terris B, Rougier P, Coriat R.

Medicine (Baltimore). 2015 Oct;94(42):e1864. doi: 10.1097/MD.0000000000001864.

15.

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.

Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY.

Oncotarget. 2015 Sep 22;6(28):26388-99. doi: 10.18632/oncotarget.4557.

16.

Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk.

Baert-Desurmont S, Charbonnier F, Houivet E, Ippolito L, Mauillon J, Bougeard M, Abadie C, Malka D, Duffour J, Desseigne F, Colas C, Pujol P, Lejeune S, Dugast C, Buecher B, Faivre L, Leroux D, Gesta P, Coupier I, Guimbaud R, Berthet P, Manouvrier S, Cauchin E, Prieur F, Laurent-Puig P, Lebrun M, Jonveaux P, Chiesa J, Caron O, Morin-Meschin ME, Polycarpe-Osaer F, Giraud S, Zaanan A, Bonnet D, Mansuy L, Bonadona V, El Chehadeh S, Duhoux F, Gauthier-Villars M, Saurin JC, Collonge-Rame MA, Brugières L, Wang Q, Bressac-de Paillerets B, Rey JM, Toulas C, Buisine MP, Bronner M, Sokolowska J, Hardouin A, Cailleux AF, Sebaoui H, Blot J, Tinat J, Benichou J, Frebourg T.

Eur J Hum Genet. 2016 Jan;24(1):99-105. doi: 10.1038/ejhg.2015.72. Epub 2015 Apr 15.

17.

Thrombocytopenia due to hypersplenism in oncological disease: partial splenic embolization during palliative treatment.

Beji H, De La Fouchardière C, Desseigne F, Thiesse P, Richioud B, Pilleul F.

Diagn Interv Imaging. 2015 Apr;96(4):383-6. doi: 10.1016/j.diii.2014.08.005. Epub 2015 Feb 27.

18.

Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.

Joly MO, Attignon V, Saurin JC, Desseigne F, Leroux D, Martin-Denavit T, Giraud S, Bonnet-Dupeyron MN, Faivre L, Auclair J, Grand-Masson C, Audoynaud C, Wang Q.

Hum Mutat. 2015 Mar;36(3):292-5. doi: 10.1002/humu.22740.

PMID:
25504677
19.

An unusual presentation of pancreatic cancer: Muscular metastasis.

Belbarka R, Fadoukheir Z, Delafouchardiere C, Desseigne F, Errihani H.

Indian J Cancer. 2014 July-September;51(3):369-370. doi: 10.4103/0019-509X.146714. No abstract available.

20.

Prodromal depression in pancreatic cancer: retrospective evaluation on ten patients.

Sebti J, Desseigne F, Saltel P.

Palliat Support Care. 2015 Jun;13(3):801-7. doi: 10.1017/S1478951514000728. Epub 2014 Jun 24.

PMID:
24959882
21.

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.

Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T.

Br J Cancer. 2014 Mar 4;110(5):1148-54. doi: 10.1038/bjc.2013.813. Epub 2014 Jan 9.

22.

A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.

Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, Letoublon C, Guimbaud R, Francois E, Ducreux M, Desseigne F, Fabre JM, Assenat E.

Ann Surg Oncol. 2013 Dec;20(13):4289-97. doi: 10.1245/s10434-013-3217-x. Epub 2013 Aug 17.

PMID:
23955585
23.

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P.

Ann Oncol. 2013 Aug;24(8):2057-61. doi: 10.1093/annonc/mdt176. Epub 2013 May 14.

24.

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.

Derbel O, Wang Q, Desseigne F, Rivoire M, Meeus P, Peyrat P, Stella M, Martel-Lafay I, Lemaistre AI, de La Fouchardière C.

BMC Cancer. 2013 Apr 23;13:200. doi: 10.1186/1471-2407-13-200.

25.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T.

J Clin Oncol. 2013 Jan 1;31(1):23-9. doi: 10.1200/JCO.2012.44.4869. Epub 2012 Dec 3.

PMID:
23213101
26.

Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.

Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M.

Oncologist. 2011;16(11):1557-64. doi: 10.1634/theoncologist.2011-0141. Epub 2011 Oct 20.

27.

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Noguès C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frébourg T, Sobol H, Lasset C, Bonaïti-Pellié C; French Cancer Genetics Network.

JAMA. 2011 Jun 8;305(22):2304-10. doi: 10.1001/jama.2011.743.

PMID:
21642682
28.

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R, Bécouarn Y, Desseigne F, Edeline J, Mitry E, Bouché O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M.

Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):48-54.

PMID:
21634054
29.

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup.

N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.

30.

Intensity-dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles.

Auclair J, Vaissière T, Desseigne F, Lasset C, Bonadona V, Giraud S, Saurin JC, Joly MO, Leroux D, Faivre L, Audoynaud C, Montmain G, Ruano E, Herceg Z, Puisieux A, Wang Q.

Genes Chromosomes Cancer. 2011 Mar;50(3):178-85. doi: 10.1002/gcc.20842. Epub 2010 Dec 9.

PMID:
21213371
31.

Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer.

Mrabti H, De la Fouchardiere C, Desseigne F, Dussart S, Negrier S, Errihani H.

J Cancer Res Ther. 2009 Oct-Dec;5(4):272-6. doi: 10.4103/0973-1482.59907.

32.

Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.

de la Fouchardière C, Négrier S, Labrosse H, Martel Lafay I, Desseigne F, Méeus P, Tavan D, Petit-Laurent F, Rivoire M, Pérol D, Carrie C.

Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):409-13. doi: 10.1016/j.ijrobp.2009.05.008. Epub 2010 Jan 29.

PMID:
20116933
33.

A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.

Ray-Coquard I, Dussart S, Goillot C, Mayeur D, Debourdeau P, Ghesquieres H, Bachelot T, Le Cesne A, Anglaret B, Agostini C, Guastalla JP, Lancry L, Biron P, Desseigne F, Blay JY.

Ann Oncol. 2009 Jun;20(6):1105-12. doi: 10.1093/annonc/mdn750. Epub 2009 Jan 27.

34.

Endobronchial metastases from colorectal adenocarcinomas: clinical and endoscopic characteristics and patient prognosis.

Coriat R, Diaz O, de la Fouchardière C, Desseigne F, Négrier S.

Oncology. 2007;73(5-6):395-400. doi: 10.1159/000136794. Epub 2008 Jun 2.

PMID:
18515979
35.

Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quénet F, Portier G, Nordlinger B.

Cancer Chemother Pharmacol. 2008 Jul;62(2):195-201. Epub 2007 Sep 28.

PMID:
17901955
36.

[Cardiac metastases and colorectal cancer: a case study].

de la Fouchardière C, Desseigne F, Orlandini F, de la Fouchardière A, Négrier S.

Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):621-3. Review. French.

37.

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.

Delord JP, Bennouna J, Artru P, Perrier H, Husseini F, Desseigne F, François E, Faroux R, Smith D, Piedbois P, Naman H, Douillard JY, Bugat R.

Br J Cancer. 2007 Aug 6;97(3):297-301. Epub 2007 Jul 17.

38.

Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation.

Auclair J, Leroux D, Desseigne F, Lasset C, Saurin JC, Joly MO, Pinson S, Xu XL, Montmain G, Ruano E, Navarro C, Puisieux A, Wang Q.

Hum Mutat. 2007 Nov;28(11):1084-90.

PMID:
17557300
39.

Estimating cancer risk in HNPCC by the GRL method.

Alarcon F, Lasset C, Carayol J, Bonadona V, Perdry H, Desseigne F, Wang Q, Bonaïti-Pellié C.

Eur J Hum Genet. 2007 Aug;15(8):831-6. Epub 2007 May 2.

40.

Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.

Duffour J, Gourgou S, Desseigne F, Debrigode C, Mineur L, Pinguet F, Poujol S, Chalbos P, Bressole F, Ychou M.

Cancer Chemother Pharmacol. 2007 Aug;60(3):383-9. Epub 2006 Nov 24.

PMID:
17124595
41.

[Rectal cancer Information dedicated to cancer patients and relatives].

Senesse P, Leichtnam-Dugarin L, Bécouarn Y, Bey P, Brusco S, Carretier J, Delavigne V, Desseigne F, Dubois JB, Ducreux M, Evrard S, Fervers B, Gérard JP, Giovannini M, Hoarau H, Lasser P, Meeus P, Philip T, Rivoire M, Ponseda P, Rouanet P, Toureille E, Voigt JJ; French National Federation of Comprehensive Cancer Centres (FNCLCC); SOR SAVOIR PATIENT; National League against Cancer; National Cancer Institute; French Hospital Federation; National Oncology Federation of Regional and University Hospitals; French Oncology Federation of General Hospitals.

Bull Cancer. 2006 Feb;93(2):179-91. French.

42.

Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing.

Auclair J, Busine MP, Navarro C, Ruano E, Montmain G, Desseigne F, Saurin JC, Lasset C, Bonadona V, Giraud S, Puisieux A, Wang Q.

Hum Mutat. 2006 Feb;27(2):145-54.

PMID:
16395668
43.

Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.

Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, Gaudin JL, Lledo G, Mackiewicz R, Gouttebel MC, Moindrot H, Boyer JD, Chassignol L, Stremsdoerfer N, Desseigne F, Moreau JM, Hedelius F, Moraillon A, Chapuis F, Bleuse JP, Barbier Y, Heilmann MO, Valette PJ.

Br J Radiol. 2002 Nov;75(899):903-8.

PMID:
12466256
44.

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.

Ychou M, Raoul JL, Desseigne F, Borel C, Caroli-Bosc FX, Jacob JH, Seitz JF, Kramar A, Hua A, Lefebvre P, Couteau C, Merrouche Y.

Cancer Chemother Pharmacol. 2002 Nov;50(5):383-91. Epub 2002 Sep 26.

PMID:
12439596
45.

Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result.

Bonadona V, Saltel P, Desseigne F, Mignotte H, Saurin JC, Wang Q, Sinilnikova O, Giraud S, Freyer G, Plauchu H, Puisieux A, Lasset C.

Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):97-104.

46.

[Curative treatment of non-metastatic esophageal cancer: concomitant chemoradiotherapy and high-dose-rate endoluminal curietherapy boost].

Taieb S, Vaillant E, Pommier P, Bonvoisin S, Desseigne F, Morignat E, Gerard JP, Mornex F.

Gastroenterol Clin Biol. 1999 Oct;23(10):1048-54. French.

47.

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, de Gramont A.

J Clin Oncol. 1999 Nov;17(11):3560-8.

PMID:
10550155
48.

Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer.

Wang Q, Lasset C, Desseigne F, Saurin JC, Maugard C, Navarro C, Ruano E, Descos L, Trillet-Lenoir V, Bosset JF, Puisieux A.

Hum Genet. 1999 Jul-Aug;105(1-2):79-85.

PMID:
10480359
49.

Neurofibromatosis and early onset of cancers in hMLH1-deficient children.

Wang Q, Lasset C, Desseigne F, Frappaz D, Bergeron C, Navarro C, Ruano E, Puisieux A.

Cancer Res. 1999 Jan 15;59(2):294-7.

50.

Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families.

Wang Q, Desseigne F, Lasset C, Saurin JC, Navarro C, Yagci T, Keser I, Bagci H, Luleci G, Gelen T, Chayvialle JA, Puisieux A, Ozturk M.

Int J Cancer. 1997 Dec 10;73(6):831-6.

Supplemental Content

Loading ...
Support Center